CINECA IRIS Institutional Research Information System

BRANCACCIO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.900
NA - Nord America 739
SA - Sud America 696
EU - Europa 308
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 40
OC - Oceania 3
Totale 3.792
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 693
BR - Brasile 542
HK - Hong Kong 499
SG - Singapore 431
VN - Vietnam 314
CN - Cina 218
KR - Corea 196
BD - Bangladesh 159
IT - Italia 144
AR - Argentina 65
DE - Germania 50
FR - Francia 37
EC - Ecuador 35
ID - Indonesia 31
RU - Federazione Russa 20
GB - Regno Unito 18
MX - Messico 18
CO - Colombia 17
ZA - Sudafrica 16
CA - Canada 13
PY - Paraguay 13
PL - Polonia 12
IN - India 11
CL - Cile 10
IQ - Iraq 9
UA - Ucraina 7
EG - Egitto 6
MA - Marocco 6
NL - Olanda 6
UZ - Uzbekistan 6
VE - Venezuela 6
JM - Giamaica 5
NP - Nepal 5
DZ - Algeria 4
AU - Australia 3
CR - Costa Rica 3
GT - Guatemala 3
IL - Israele 3
PK - Pakistan 3
SV - El Salvador 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
ES - Italia 2
IR - Iran 2
JP - Giappone 2
KE - Kenya 2
PE - Perù 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
ET - Etiopia 1
FI - Finlandia 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SE - Svezia 1
SN - Senegal 1
TG - Togo 1
TR - Turchia 1
Totale 3.686
Salva come PNG Salva come JPEG
Città #
Hong Kong 498
San Jose 258
Seoul 196
Singapore 160
Ho Chi Minh City 111
Ashburn 97
Chicago 74
Hanoi 65
Beijing 49
Frankfurt am Main 44
São Paulo 44
New York 25
Haiphong 19
Sona 19
Da Nang 18
Dallas 16
Rio de Janeiro 16
Santa Clara 16
Mexico City 13
Hillsboro 12
Buffalo 11
Guayaquil 11
Belo Horizonte 10
Biên Hòa 10
Milan 10
Quito 10
Los Angeles 9
Manaus 9
Padua 9
Brasília 8
Curitiba 8
Naples 8
Porto Alegre 8
Rome 8
Warsaw 8
Buenos Aires 7
Bari 6
Campinas 6
Florence 6
Fortaleza 6
Goiânia 6
Hải Dương 6
Phoenix 6
Piscataway 6
Quảng Ngãi 6
Tashkent 6
Asunción 5
Boardman 5
Johannesburg 5
Ninh Bình 5
Osasco 5
Palermo 5
Phủ Lý 5
Piracicaba 5
Santo André 5
Sumaré 5
Bauru 4
Bogotá 4
Bragança Paulista 4
Can Tho 4
Casablanca 4
Franca 4
Guarulhos 4
Ha Long 4
Joinville 4
Macaé 4
Orem 4
Recife 4
Roubaix 4
Salvador 4
São Gonçalo 4
Wroclaw 4
Amsterdam 3
Bandung 3
Belford Roxo 3
Bologna 3
Cairo 3
Campina Grande 3
Cape Town 3
Caracas 3
Catania 3
Caxias do Sul 3
Chapecó 3
Charlotte 3
Criciúma 3
Dhaka 3
Florianópolis 3
Formosa 3
Hortolândia 3
Huế 3
Ibirité 3
Itaquaquecetuba 3
Jacksonville 3
Jakarta 3
Juiz de Fora 3
Limburg an der Lahn 3
London 3
Lấp Vò 3
Maceió 3
Marília 3
Totale 2.152
Salva come PNG Salva come JPEG
Nome #
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 89
An increase in the levels of middle surface antigen characterizes patients developing hbv-driven liver cancer despite prolonged virological suppression 82
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 68
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 62
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 61
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 57
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 56
Virological patterns of HCV patients with failure to interferon-free regimens 55
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 55
AISF position paper on HCV in immunocompromised patients 55
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 54
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 52
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 51
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 51
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 50
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 48
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years 48
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 47
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 47
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 46
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 46
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis 45
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 45
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 44
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 43
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 43
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 42
Recent breakthroughs in the treatment of chronic hepatitis Delta 41
Prophylaxis of hepatitis B virus (HBV) re-infection in liver transplantation: Is the reappearance of hepatitis B surface antigen (HBsAg) significant? 41
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 41
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 40
null 40
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 40
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply 39
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 39
CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis 39
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 38
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 38
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency 37
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare 36
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 36
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 36
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues 36
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 36
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 36
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma 35
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 35
Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants 35
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 35
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 35
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 35
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 34
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 34
Hepatitis c late relapse in patients with directly acting antiviral- related sustained virological response at week 12 34
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 34
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues 33
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 33
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 33
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 32
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 32
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 32
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 32
Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with Peg-Interferon and Ribavirin 32
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 32
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 31
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 31
Association between sustained virological response and adverse liver-related events in patients with decompensated HCV cirrhosis 30
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 30
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 30
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy 30
Liver transplantation for t2 hepatocellular carcinoma during the covid-19 pandemic: A novel model balancing individual benefit against healthcare resources 30
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 30
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 29
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 29
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays 29
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 29
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 29
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 29
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 29
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 29
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 28
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 28
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 28
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 28
Hepatitis delta infection in Italian patients: towards the end of the story? 28
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 27
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 27
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 26
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 26
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 26
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 26
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 25
Hepatitis C Virus Clearance in Older Adults 25
Letter Comment to: Which saint to pray for fighting against COVID? A short survey. By Perciaccante A et al 24
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study 24
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +  23
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 23
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 23
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 20
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 19
Totale 3.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025859 0 0 0 0 0 0 0 0 137 492 208 22
2025/20262.853 155 97 498 666 211 53 28 409 211 134 238 153
2026/202780 44 36 0 0 0 0 0 0 0 0 0 0
Totale 3.792